Ldr Holding Corp (LDRH): Patrick Richard , EVP, European Sales, Medical of Ldr Holding Corp sold 25,000 shares on Apr 15, 2016. The Insider selling transaction was reported by the company on Apr 19, 2016 to the Securities and Exchange Commission. The shares were sold at $27.60 per share for a total value of $689,892.50 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Apr 13, 2016, Patrick Richard (EVP, European Sales, Medical) sold 25,000 shares at $26.50 per share price.On Mar 11, 2016, G. Joseph Ross (Exec VP Global Marketing) sold 17,613 shares at $23.07 per share price.Also, On Nov 12, 2015, Robert Mcnamara (Chief Financial Officer) sold 19,373 shares at $26.15 per share price.On Jul 13, 2015, Christophe Lavigne (President & CEO) sold 20,000 shares at $40.07 per share price.
LDR Holding Corp: On Monday, Apr 18, 2016 heightened volatility was witnessed in LDR Holding Corp which led to swings in the share price. The shares opened for trading at $28.08 and hit $28.525 on the upside , eventually ending the session at $28, with a gain of 0.04% or 0.01 points. The heightened volatility saw the trading volume jump to 3,06,623 shares. The 52-week high of the share price is $47.12 and the company has a market cap of $818 M . The 52-week low of the share price is at $16.33.
Company has been under the radar of several Street Analysts.LDR Holding Corp is Initiated by Gabelli & Co to Buy and the brokerage firm has set the Price Target at $38. The Rating was issued on Apr 15, 2016.LDR Holding Corp is Downgraded by Wells Fargo to Market Perform. Earlier the firm had a rating of Outperform on the company shares. The Rating was issued on Jan 22, 2016.
Currently the company Insiders own 7% of LDR Holding Corp shares according to the proxy statements.Institutional Investors own 90.28% of LDR Holding Corp shares.During last six month period, the net percent change held by insiders has seen a change of -38.73%.
LDR Holding Corporation is a global medical device company. The Company is focused on designing and commercializing surgical technologies for the treatment of patients suffering from spine disorders. The Company’s primary products are based on its VerteBRIDGE fusion and Mobi non-fusion platforms both of which are designed for applications in the cervical and lumbar spine. The Company’s VerteBRIDGE products are designed around its plating technology that enables surgeons to implant VerteBRIDGE devices with direct visualization of the disc and to affix the devices to the vertebrae from inside the spinal disc space. The Company’s Mobi non-fusion platform is highlighted by Mobi-C a cervical disc replacement device with a patented mobile bearing core that is designed to replicate the natural anatomical movement of the spine by facilitating independent bending and twisting similar to a healthy disc.